Epilepsy is a chronic heterogenous condition in which patients experience recurrent and seemingly unprovoked seizures. Epilepsy is a common condition with about 46 million people worldwide suffering active epilepsy. Despite being common, classifying, diagnosing and treating epilepsy can be difficult.
Paediatric epilepsy treatment focuses on managing clinical seizures and the optimal use of current anti-epileptic drugs (AED) may allow more patients to reduce or attain freedom from seizures. While there is an abundance of choice in AEDs, treatment is most effective when AED activity is matched to seizure type which necessitates accurate seizure classification.
The use of AEDs is ineffective in around one-third of adult epilepsy cases and so alternative methods of treating drug-resistant epilepsy are available. These include surgery, neuromodulation and a ketogenic diet.
To find out more about epilepsy visit our dedicated Learning Zone, which contains expert-led information on paediatric epilepsy, focal seizures in adults and the treatment options available.
Related news and insights
Eton Pharmaceuticals, Inc. announced that it has sold its neurology portfolio to Azurity Pharmaceuticals. The portfolio includes Eton’s lamotrigine (ET-105), zonisamide (ET-104), and topiramate (ET-101) product candidates, which have all been submitted to the FDA as new drug applications and are currently under review by the agency.
SK Biopharmaceuticals announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of cenobamate for the adjunctive treatment of focal-onset (partial-onset) seizures with or without secondary generalization in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least two anti-seizure medications (ASMs).
Marinus Pharmaceuticals announced it has received a positive response from the FDA that the efficacy and safety data resulting from the company’s pivotal Phase III Marigold Study on the use of oral ganaxolone in children and young adults with CDKL5 deficiency disorder (CDD) appear sufficient to support the filing of a New Drug Application (NDA).
This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.